Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...

Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.

Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.3 which represents a decrease of $-0.07 or -2.95% from the prior close of $2.37. The stock opened at $2.34 and touched a low of ...

Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.34 which represents a slight increase of $0.05 or 2.18% from the prior close of $2.29. The stock opened at $2.29 and ...

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a biopharmaceutical company specializing in the development of oral treatments for inflammatory diseases, announced today that Martin Auster ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...